Low risk kidney transplant recipients kidney transplantation, very low dose thymoglobulin, low immunological risk, induction therapy, rejection
Conditions
Interventions
thymoglobulin 25 mg for 3 days,basiliximab 20 mg at day 0 and day 4
Active Comparator Drug,Active Comparator Drug
very low dose ATG,basiliximab
Sponsors
Department of Nephrology, Siriraj Hospital
Eligibility
Sex/Gender
All
Age
20 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. First kidney transplant recipients from a living or deceased donor 2. Age > 20 years 3. Peak and current PRA < 20%, or Single Antigen Bead (SAB) assay < 2,000 MFI 4. Absence of Donor-Specific Antibodies (DSA) in both peak and current sera 5. Cold Ischemia Time (CIT) < 24 hours
Exclusion criteria
Exclusion criteria: 1. Multiple-organ transplantation 2. Recipients with HIV infection 3. High-risk CMV serostatus (Donor CMV IgG positive / Recipient CMV IgG negative) 4. Preformed donor specific HLA antibody 5. ABO-incompatible kidney transplantation 6. HLA identical kidney transplantation 7. Hypersensitivity to thymoglobuliin 8. Baseline leukopenia (wbc count < 2,500 cells/ul ) 9. Recipients who denied participation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Rejection 1 year after kidney transplantation Occurrence of biopsy-proven rejection | — |
Secondary
| Measure | Time frame |
|---|---|
| Mortality 1 year after kidney transplantation Incidence of mortality,Graft loss 1 year after kidney transplantation Incidence of graft loss,dnDSA (De novo DSA) 1 year after kidney transplantation Incidence of dnDSA,CMV infection 1 year after kidney transplantation Incidence of CMV infection that required anti-viral therapy,Renal function 1 year after kidney transplantation eGFR,Serious infection 1 year after kidney transplantation Incidence of serious infection that required hospitalization | — |
Countries
Thailand
Contacts
Public ContactAttapong Wongwiwatana
Nephrology Department, Siriraj Hospital, Mahidol University
Outcome results
None listed